Dalteparin Doesn't Seem to Prevent Pregnancy Complications in Women with Thrombophilia — Physician’s First Watch
Dalteparin Doesn't Seem to Prevent Pregnancy Complications in Women with Thrombophilia
By Kelly Young
Edited by William E. Chavey, MD, MS
Prenatal dalteparin does not reduce the incidence of pregnancy loss, placenta-mediated pregnancy complications, or venous thromboembolism among high-risk women with thrombophilia, according to an open-label trial in the Lancet.
Some 300 pregnant women with confirmed thrombophilia and at least one risk factor for pregnancy complications were randomized to receive either a daily self-injection of dalteparin (a low-molecular-weight heparin) or no dalteparin.
Overall, 18% of patients experienced the primary endpoint — a composite of major venous thromboembolism, severe or early-onset preeclampsia, birth of a small-for-gestational-age infant, or loss of pregnancy — with no significant difference between the groups. However, minor bleeding events were twice as common in the dalteparin group as in the control group (20% vs. 9%).
The authors say their findings "suggest that women with thrombophilia should not be prescribed low-molecular-weight heparin to prevent these complications unless further research suggests benefit."